Share This Page
Drugs in ATC Class M01CB
✉ Email this page to a colleague
Drugs in ATC Class: M01CB - Gold preparations
Market dynamics and patent landscape for ATC Class M01CB (Gold preparations): exclusivity timelines, Orange Book status, and generic/biosimilar entry risk
Gold preparations remain a niche disease-modifying option for inflammatory arthritis, with market access largely driven by country-level reimbursement and supply continuity rather than blockbuster innovation. The patent landscape is fragmented across legacy gold salts and combinations, with most primary patents having lapsed in major markets. The practical IP barriers for entrants are therefore less about new active-ingredient chemistry and more about (1) formulation and manufacturing process patents tied to specific gold salts (auranofin; gold sodium thiomalate; auranofin capsules; injectable gold salts) and (2) any late-life method-of-use or second-generation filings for specific indications or dosing regimens.
What patents protect ATC M01CB “gold preparations” (auranofin and gold salts) in the US, EU, and UK?
Gold preparations under ATC M01CB are not a single molecular entity. The patent estate typically splits by active ingredient:
- Auranofin (oral gold; M01CB02 in many ATC mappings)
- Gold sodium thiomalate / sodium aurothiomalate (injectable gold salt)
- Gold salts used in rheumatology under various brand labels, sometimes including combinations or specific salts/forms
What does protection look like by patent type?
In legacy small-molecule gold products, current protection most often appears as:
- Formulation/process patents (tablet/capsule fill, dissolution rate control, sterile manufacturing for injectables, stability-indicating manufacturing controls).
- Second medical use patents (new dosing schedules or patient subsets).
- Salt form and polymorph-related filings are less common for gold salts than for typical organic APIs, because gold salts are often defined by established ionic compositions and pharmacopeial specs.
How many active ingredient patents remain live?
Across major jurisdictions, patents covering the core gold actives from first approvals are generally expired or near-expired due to product launch dates spanning decades. Remaining enforceable patents are usually tied to:
- a specific dosage form (capsules vs injectables)
- a manufacturing route (sterility assurance, particle size, crystallization control)
- a specific label or method-of-use (if filed later)
Because enforcement typically requires jurisdiction-specific claim construction and Orange Book/EP Register linkage, the live-in-force share is best evaluated per brand, per dosage form, and per listed patents in FDA/EPB registers.
When does exclusivity end for gold preparations, and what drives the last generic switch?
For small-molecule gold products, “exclusivity” usually means:
- patent term (and any PTA/PTE adjustments where applicable)
- regulatory exclusivity (rare for old gold products because original marketing dates long predate modern Hatch-Waxman exclusivity frameworks)
- orphan, pediatric, and other exclusivity only where they apply (not a common fit for broad inflammatory arthritis indications)
Key exclusivity mechanics that matter for M01CB entrants
Patent term typically dominates. “Last generic switch” timing depends on whether any later-filed patents cover:
- specific formulation (e.g., capsule composition or coating)
- specific manufacturing steps that are hard to replicate
- any method-of-use that is still enforceable when a label is updated or a new use is pursued
What is the typical generic pathway risk profile?
For gold products, risk is less about biosimilar-style comparability and more about:
- Paragraph IV exposure (if the reference product has Orange Book-listed patents still in force)
- noninfringement vs invalidity defenses (often the only available route once a listed patent is close to expiration)
- launch-readiness (process changes that impact gold salt stability, sterility, and particle attributes)
What is the Orange Book status of gold preparations (M01CB) and which patents are listed?
Orange Book listing is decisive for Paragraph IV strategy in the US. The relevant data to produce a correct, decision-grade Orange Book mapping includes:
- specific NDA/BLA numbers for gold products under M01CB
- Orange Book patent lists (US patents, expiration dates, regulatory extensions)
- whether those listings are tied to the specific dosage form/strength
A complete Orange Book status summary requires item-level register extraction by product and dosage form. Without that product-to-register mapping, a market-wide generic count would be unreliable, and enforcement mapping could be wrong. Under strict accuracy constraints, no actionable Orange Book patent table is provided here.
Which companies own key patent estates for auranofin and injectable gold salts?
The ownership pattern for gold preparations is mostly legacy:
- original brand holders and their successors for the first-generation gold salts
- regional distributors for supply-linked injectable formats
- generic manufacturers that have already obtained approvals, sometimes acquiring rights tied to specific formulations or processes
For business planning, the relevant ownership unit is not “ATC class,” but:
- NDA-linked product at the dosage form level
- EP family aligned with the specific salt/formulation
A reliable “who owns what” list again requires register-level extraction by identified reference products.
How strong is the patent estate for gold preparations, and what does “enforceable IP” usually cover?
For gold preparations, “strength” is usually determined by whether claims are:
- composition of matter (rare for recent enforceable gold estates)
- process claims (often the most litigated remaining layer)
- formulation claims that control dissolution, stability, or sterility outcomes
- method-of-use claims that map to label language
Where do entrants typically get blocked?
- Sterile injectable gold salts: manufacturing process constraints can be nontrivial to design around.
- Stability and shelf-life for gold salts: even if API is the same, formulation and manufacturing specs can sustain infringement arguments.
- Label-specific dosing: method-of-use claims can block a narrow label launch even if a composition is otherwise generically available.
What patent litigation affects gold preparations, including Paragraph IV challenges and settlements?
Litigation risk for gold products is concentrated in:
- US Paragraph IV suits against Orange Book listed patents
- EU national actions tied to EP family claims
- UK High Court actions under EP-derived rights (if asserted)
A litigation-and-settlement map needs:
- case dockets by product NDA
- court/jurisdiction records
- settlement agreement dates and “carve-out” terms (authorized generic, interim supply, launch timing)
Without an identified product list and docket mapping, a litigation summary would risk being inaccurate. No litigation table is provided here.
How do gold preparations compare with other DMARDs on IP risk for generics?
Gold preparations differ from many modern DMARDs:
- They are mostly small molecules or defined gold salts.
- They do not carry the same post-approval biologics exclusivity dynamics.
- Their enforceable patent layer is often process/formulation, which can still support injunctions but typically has narrower market scope by dosage form and manufacturing approach.
For entrants, the main differentiator is whether injectable gold salts have any enforceable formulation/manufacturing patents not yet designed around.
What generic entry risks exist for auranofin vs injectable gold sodium thiomalate?
Auranofin (oral)
Generic risk typically centers on:
- capsule composition, excipients, and stability profile
- dissolution characteristics that can map to formulation claims
- label method-of-use limitations
If no Orange Book-listed patents remain, an oral generic can often launch more quickly, subject to FDA review and labeling.
Injectable gold salts
Generic risk centers on:
- sterile manufacturing and sterility assurance claims
- particle size/crystallinity attributes
- stability and container-closure system claims
Even when API is public, process-specific infringement theories are more common for injectables.
Which formulation patents matter most for gold preparations (oral and injectable)?
Formulation patents in legacy gold estates often cover:
- capsule or tablet formulations with specified excipient blends
- coating or dissolution modifiers affecting release profile
- lyophilized or sterile reconstitution instructions for injectables
- stabilizer systems for gold salt oxidation control
- container/closure and compatibility where claimed as part of a formulation package
Process patents in parallel often cover:
- synthesis or crystallization conditions for gold salt batches
- purification steps that affect impurity profiles
- sterilization processes and validation steps for injectables
How do manufacturing/IP barriers affect time-to-market for M01CB generic entrants?
For gold salts, barriers are practical as much as legal:
- GMP complexity for sterile products
- validated stability data requirements
- tight impurity and specification control due to metal chemistry variability
- regulatory CMC work to demonstrate comparability in sterility, potency, and stability
Even if patents lapse, time-to-market can stay constrained by the CMC package and batch-to-batch consistency needs.
What is the commercial outlook for gold preparations given patent and market dynamics?
Commercially, the market is shaped by:
- steady but limited use in refractory inflammatory arthritis settings
- competitive pressure from broader DMARD classes (conventional synthetic and biologic therapies)
- inventory and supply continuity for injectables
- reimbursement tightening in many markets
Because the patent estate is mostly legacy, price-driven competition is usually the dominant dynamic when patent lock ends. Where injectables face process-linked IP constraints, supply continuity and quality systems can keep competition from fully eroding prices.
Key Takeaways
- M01CB “gold preparations” is not one patent estate; it splits by active ingredient and dosage form (oral auranofin vs injectable gold salts).
- Most primary patents are likely expired in major markets; remaining enforceable rights typically sit in formulation and manufacturing/process claims.
- US Paragraph IV risk depends on Orange Book listings per NDA and strength; a class-level summary cannot substitute for product-level register mapping.
- Injectable gold salts carry the highest non-infringement and CMC execution risk because process and sterility requirements often map to claim scope.
- Commercial dynamics are supply and reimbursement driven more than patent-driven innovation for this ATC class.
FAQs
1) Do gold preparations have biosimilar risk like biologics?
No. Gold preparations are small-molecule gold salts/compounds, so the competitive framework is generic/ANDA, not biosimilar licensing.
2) What patents typically block auranofin generics?
When present late in the lifecycle, the most relevant blockers are usually formulation and method-of-use patents tied to label-specific dosing or release characteristics.
3) What patent strategy is used for injectable gold salts?
Generic entrants usually focus on process design-around for sterile manufacturing and stability-control steps, paired with label carve-outs if any method-of-use patents remain.
4) What matters most for launch timing in the US?
Orange Book patent status for the specific NDA strength and the resulting Paragraph IV litigation and settlement posture. Class-level timing cannot replace per-product register evaluation.
5) Why can injectables stay expensive even after API patent expiry?
CMC complexity, supply constraints, sterile manufacturing validation cost, and any residual formulation/process patents can reduce the number of viable market entrants.
References (APA)
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- European Patent Register. European Patent Register (EPO). https://register.epo.org/
More… ↓
